Apolipoprotein Proteomic Profiling for the Prediction of Cardiovascular Death in Patients with Heart Failure

Area of Science:

• Cardiology
• Proteomics
• Biomarker Discovery

Background:

• Risk stratification is essential for managing chronic systolic heart failure (HF).
• Identifying new biomarkers can improve prognosis evaluation and understanding of HF.
• Current methods may not fully capture HF patient risk profiles.

Purpose of the Study:

• To identify novel apolipoprotein (Apo) biomarkers for risk stratification in chronic systolic heart failure (HF).
• To improve prognostic evaluation and understand HF physiopathology through proteomic analysis.

Main Methods:

• Proteomic profiling of 15 apolipoproteins (Apo) was performed using LC-MRM-MS.
• 198 patients with chronic systolic HF were studied, matched for age, sex, and HF etiology.
• Patients were divided into two groups: those who died from cardiovascular causes within three years and those who survived.

Main Results:

• Univariate analysis showed lower levels of Apo-B100 and -L1, and higher levels of Apo-C1, -J, and -M in patients who died.
• Apo-C1, Apo-J, and Apo-M individually improved the prediction of cardiovascular death in the final statistical model.
• Pathway analysis linked these three apolipoproteins to lipid metabolism, atherosclerosis signaling, and retinoid X receptor activation.

Conclusions:

• Proteomic profiling of apolipoproteins using LC-MRM-MS shows promise for clinical risk stratification in HF patients.
• Apo-C1, Apo-J, and Apo-M are identified as potential biomarkers for predicting cardiovascular mortality in HF.
• These findings contribute to a better understanding of HF physiopathology and advanced therapy selection.